Rami Levin
Directeur Général chez ImStem Biotechnology, Inc.
Profil
Rami Levin is currently the Chief Executive Officer at ImStem Biotechnology, Inc. and also holds a position at Swedish Orphan Biovitrum, Inc. as President.
Prior to his current roles, he served as the President & Chief Executive Officer at Saniona AB from 2020 to 2022.
He also held positions at EMD Serono, Inc. as Vice President-Marketing and at Swedish Orphan Biovitrum AB as Head-North America.
Mr. Levin received his undergraduate degree from Tel-Aviv University and his MBA from Recanati Business School Tel Aviv University.
Postes actifs de Rami Levin
| Sociétés | Poste | Début |
|---|---|---|
ImStem Biotechnology, Inc.
 ImStem Biotechnology, Inc. Medical SpecialtiesHealth Technology ImStem Biotechnology, Inc. operates as a biotechnology company. It focuses on developing cell therapeutic products. Its cell therapeutic products are derived from human pluripotent stem cells for tissue repair, treatment of neural, heart, vascular, blood system diseases and autoimmune diseases. The company was founded by Xinghua Victor Pan, Ren-He Xu, Michael Men, and Xiaofang Wang in June 2012 and is headquartered in Farmington, CT. | Directeur Général | 02/09/2022 |
Anciens postes connus de Rami Levin
| Sociétés | Poste | Fin |
|---|---|---|
| SANA AB | Directeur Général | 30/04/2022 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Swedish Orphan Biovitrum, Inc.
 Swedish Orphan Biovitrum, Inc. Pharmaceuticals: MajorHealth Technology Swedish Orphan Biovitrum, Inc. operates as an international rare disease company providing access to treatments that make a significant difference for people with rare diseases. Its business areas include haemophilia, immunology and specialty care. The company is headquartered in Waltham, MA. | President | - |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Sales & Marketing | - |
Formation de Rami Levin
| Tel-Aviv University | Undergraduate Degree |
| Recanati Business School Tel Aviv University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| SANA AB | Health Technology |
| Entreprise privées | 3 |
|---|---|
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Swedish Orphan Biovitrum, Inc.
Swedish Orphan Biovitrum, Inc. Pharmaceuticals: MajorHealth Technology Swedish Orphan Biovitrum, Inc. operates as an international rare disease company providing access to treatments that make a significant difference for people with rare diseases. Its business areas include haemophilia, immunology and specialty care. The company is headquartered in Waltham, MA. | Health Technology |
ImStem Biotechnology, Inc.
ImStem Biotechnology, Inc. Medical SpecialtiesHealth Technology ImStem Biotechnology, Inc. operates as a biotechnology company. It focuses on developing cell therapeutic products. Its cell therapeutic products are derived from human pluripotent stem cells for tissue repair, treatment of neural, heart, vascular, blood system diseases and autoimmune diseases. The company was founded by Xinghua Victor Pan, Ren-He Xu, Michael Men, and Xiaofang Wang in June 2012 and is headquartered in Farmington, CT. | Health Technology |